Efficacy and safety of acupoint thread embedding for melasma: a systematic review and meta-analysis
Frontiers in Medicine · 16.11.2026 · 13
DOI: 10.3389/fmed.2026.1991250 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Medicine, online erschienen am 16.11.2026. Verfasst von Xiao Guo und 5 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Melasma is a chronic, acquired hyperpigmentation disorder that predominantly affects reproductive-aged women, with prevalence reaching 9%–50% in high-risk populations; local adverse reactions and modest sustained efficacy limit conventional therapies. Acupoint thread embedding (ATE), a technique that provides sustained acupoint stimulation, has shown preliminary promise; however, no updated systematic review has synthesized the accumulating evidence.
Methods
We searched nine bibliographic databases (PubMed, Embase, Cochrane Library, Web of Science, Scopus, CNKI, Wanfang, VIP, and CBM) and two trial registries (ClinicalTrials.gov and ICTRP) from inception to June 2026 for randomized controlled trials (RCTs) evaluating ATE for melasma. The primary outcome was the total effective rate; secondary outcomes included Melasma Area and Severity Index (MASI) scores, recurrence, and adverse events (AEs). Risk of bias was assessed using RoB 2, and evidence certainty was evaluated using GRADE. Random-effects models were used for meta-analysis.
Results
Nineteen RCTs involving 1,539 patients were included; 18 contributed to meta-analysis, and all were at high risk of bias. In the primary add-on analysis (ATE plus co-intervention vs. the same co-intervention alone; n = 9), ATE increased the total effective rate [risk ratio [RR] = 1.24, 95% confidence interval [CI]: 1.16–1.33; I 2 = 0%]. Pooling all comparison designs ( n = 18) yielded an RR of 1.24 (95% CI: 1.17–1.31; I 2 = 22%), potentially overestimating the incremental effect of ATE. For MASI scores, the pooled mean difference (MD), calculated as the pretreatment score minus the post-treatment score, was 2.81 (95% CI: 0.02–5.61; I 2 = 94%), favoring ATE; however, substantial heterogeneity rendered this finding exploratory. Recurrence showed a nonsignificant trend favoring ATE (RR = 0.53, 95% CI: 0.25–1.12; n = 2). Reported AEs were mainly mild and transient. No serious AEs were reported in studies providing safety data, but incomplete reporting precluded reliable safety assessment.
Conclusion
ATE combined with co-interventions may improve the total effective rate and MASI scores in patients with melasma. However, the certainty of evidence was very low, and the MASI findings were highly heterogeneous and exploratory. Rigorous, high-quality RCTs are needed to establish its efficacy and safety. Registration PROSPERO (CRD420261427231; https://www.crd.york.ac.uk/PROSPERO/recorddashboard ).
Zitieren
APA
Guo, X., Wang, Z., Xiao, D., Yi, D., Weng, H., & Huang, N. (2026). Efficacy and safety of acupoint thread embedding for melasma: a systematic review and meta-analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1991250
Vancouver
Guo X, Wang Z, Xiao D, Yi D, Weng H, Huang N. Efficacy and safety of acupoint thread embedding for melasma: a systematic review and meta-analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1991250
BibTeX
@article{Guo2026,
author = {Guo, Xiao and Wang, Zhiyao and Xiao, Dingyuan and Yi, Dongmu and Weng, Huilan and Huang, Ning},
title = {Efficacy and safety of acupoint thread embedding for melasma: a systematic review and meta-analysis},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1991250}
}
EUVIMED